Incyte Corporation (INCY) Stock Analysis

Incyte Corporation (INCY) is a publicly traded company in the HEALTHCARE sector. It trades at $92.24, carries a market capitalization of $19.10B, a price-to-earnings ratio of 13.50. This page summarizes the public market data, fundamentals, and frequently asked questions for INCY, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $92.24
• Market Cap: $19.10B
• P/E Ratio: 13.50
• EPS: $7.08
• 52-Week High: $112.29
• 52-Week Low: $66.30

Market Sentiment

Incyte Corporation currently has a Bullish sentiment score of 0.19.

About Incyte Corporation

Incyte Corporation, based in Wilmington, Delaware, is a leading biopharmaceutical firm specializing in the development of innovative therapies for oncology and other critical diseases. Founded in 1991, the company has established a strong commercial presence with its flagship product, Jakafi, which is used to treat myelofibrosis and polycythemia vera, while also advancing a diverse pipeline of candidates targeting various cancer types. Incyte's dedication to precision medicine and its collabo...

GNG Research Analysis

GNG Research scores Incyte Corporation (INCY) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INCY.

Frequently Asked Questions

Does INCY pay dividends?

Incyte Corporation (INCY) does not currently pay a regular dividend.

What is INCY's P/E ratio?

Incyte Corporation has a price-to-earnings (P/E) ratio of 13.50.

What is INCY's market cap?

Incyte Corporation (INCY) has a market capitalization of $19.10B with a current stock price of $92.24.